RxDoctor Payments Data

Mark Schneyer, MD

Otolaryngology · Owings Mills, MDNPI 1952523128

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,167 of the $5,988 with a category attached, or 86.3%. 21 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 26.4% of the total. Reporting peaked in 2024 at $1,905 and has fallen 71.6% since, to $542 in 2025.

$5,988in general payments, 2019–2025

Across 211 payments — averaging $28.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$2K
  • Neurent Medical Limited$1K
  • Optinose US, Inc.$827
  • GSK$786
  • Sanofi$576
  • Intersect ENT, Inc.$275
  • plus $813 from 15 others

What the payments were for

  • Consulting fees$82014%
  • Food & beverage$5,16786%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,988 in reported general payments places this provider in the 85th percentile of 222 otolaryngology providers in Maryland.

See all otolaryngology providers in Maryland

Medicare billing

Part B allowed, 2024
$373,455
Medicare patients
929
Services billed
3,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Azelastine-FluticasoneAzelastine/Fluticasone19$4,270
Ipratropium Bromide85$2,910
Famotidine169$2,333
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth21$2,247
Azelastine Hcl70$1,916
Fluocinolone Acetonide Oil45$1,491
Ofloxacin27$1,126
Fluticasone Propionate55$1,094
Mupirocin36$285
Methylprednisolone27$181
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav23$163
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid13$106
Azithromycin12$70
Prednisone30$63

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Owings Mills

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →